Jeffrey Cranmer

@jeff_cranmer

Executive Editor, . All opinions expressed are my own.

Vrijeme pridruživanja: listopad 2014.

Tweetovi

Blokirali ste korisnika/cu @jeff_cranmer

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @jeff_cranmer

  1. prije 10 sati

    will provide its AS03 adjuvant technology to enhance vaccines that are being funded by . Story:

    Poništi
  2. proslijedio/la je Tweet

    Folks - is continuing to cover the outbreak, which is outside the paywall. This contains the therapeutic & preventive developments, policy actions, and biopharma response.

    Poništi
  3. 1. velj

    Approval of therapy huge step in right direction for food allergy patients, families, lends important validation to long-held theory that desensitization is effective to treat food allergies, writes 's

    Poništi
  4. proslijedio/la je Tweet
    1. velj

    Summary of the week. Be prudent. Prepare for the worst and Hope for the best. Follow the data and listen to the science. Do everything we can in the meantime. The cost of under reacting is worse than some worry. This is NOT an existential threat, but there are many unknowns.

    Poništi
  5. 1. velj

    20% of industry-sponsored clinical trials in China have a site in Wuhan, the epicenter of the 2019-nCoV outbreak. Most of those are late-stage.

    Poništi
  6. 31. sij

    . declares #2019-nCoV public health emergency. Another declaration needed for to issue Emergency Use Authorizations for use of unapproved diagnostics, drugs or vaccines 's reports:

    Poništi
  7. 31. sij

    's complete. 's Steve Bates speaks with 's about the trade group's priorities in shaping UK life sci sector's new relationship w/EU

    Poništi
  8. 31. sij
    Poništi
  9. proslijedio/la je Tweet
    31. sij

    A dozen #2019-nCoV vaccine development programs have been announced, five efforts to discover and develop therapeutic antibodies.

    Poništi
  10. 30. sij

    A program rolled out Thursday allows states to create restrictive drug formularies while also receiving rebates from drug manufacturers. It's likely headed for the courts, writes

    Poništi
  11. 30. sij

    Arch co-leads $14M series A for Vizgen, which aims to overcome capacity limitations of single-cell RNA imaging tech. Co-founder David Walt is scientific founder of 2 other Arch portfolio cos: & via in

    Poništi
  12. proslijedio/la je Tweet

    🚨BREAKING🚨 "For all of these reasons, I am declaring a public health emergency of international concern over the global outbreak of ."-

    Prikaži ovu nit
    Poništi
  13. proslijedio/la je Tweet

    "The speed with which detected the outbreak, isolated the virus, sequenced the genome and shared it with WHO and the world are very impressive. So is 🇨🇳’s commitment to transparency and to supporting other countries"-

    Prikaži ovu nit
    Poništi
  14. proslijedio/la je Tweet
    Prikaži ovu nit
    Poništi
  15. 30. sij

    W/ $45M series B led by Decheng, looks to capitalize on IP position around alternative enzyme, expand gene editing capabilities beyond Dx to therapeutic applications. 's talks w/ CEO Trevor Martin:

    Poništi
  16. proslijedio/la je Tweet
    30. sij

    Center for Communicable Disease Dynamics offers ‘tweetorial’ on coronavirus

    Poništi
  17. 30. sij

    Black Diamond raises $200M in . The precision oncology company had raised $194M in venture $ since 2014 launch from VCs including Versant (31% stake), NEA (8%), RA (5%)

    Poništi
  18. proslijedio/la je Tweet
    30. sij

    CVS eliminating co-pays for insulin and diabetes meds. A step in the right direction say biopharma leaders who want to uphold the social contract. Via in

    Poništi
  19. 30. sij

    2/2 Reid succeeds Steven Holtzman, who is retiring after a decades-long career at Decibel, , and Millennium. At Infinity and Millennium, he was responsible for a string of blockbuster deals with larger companies.

    Prikaži ovu nit
    Poništi
  20. 30. sij

    1/2 Under the leadership of incoming CEO Laurence Reid, co begins new chapter in drug discovery w/narrowed focus on inner ear cell regeneration and programs in balance disorders. via

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·